fluxed 2 hr and allowed to cool. The crystals which formed were dissolved in MeOH, neutralized with NaOH, and purified by fractional recrystallization (C<sub>6</sub>H<sub>6</sub>-Me<sub>2</sub>CO) yielding two isomers.

The substituted 2-benzylidene-1,3-indanedione was prepared by dissolving equal molar quantities of the aldehyde and indanedione in absolute EtOH, heating until crystal formation occurred, cooling, filtering, and recrystallizing from 95% EtOH and Me<sub>2</sub>CO.

## 6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene<sup>1</sup>

CARL TABB BAHNER, DAVID H. BROTHERTON, HAROLD KINDER, WILLIAM RICH, STUART L. WATSON, JR., AND JOHN ZIRKLE

Department of Chemistry, Carson-Newman College, Jefferson City, Tennessee 37760

Received March 6, 1969

6-Aminochrysene (I) has been reported to be active against mammary carcinoma.<sup>2</sup> Noting that a *cis*-4-aminostilbene structure can be seen in one of the Kekule formulas for this compound, we prepared 6-dimethyl-aminochrysene (Table I) by methylating I with MeI for

Table I
Analogs of 4-(4-Dimethylamino)stilbene

	TENNESSES OF T (I DIMETHING) STEEDENS						
No.	Compd	Mp, °C <sup>a</sup>	$Formula^b$				
1	6-Dimethylaminochrysene	$101-102^{c}$	$C_{20}H_{17}N$				
2	2-(4-Aminophenyl)indole	$215^d$	$C_{14}H_{12}N_2$				
3	3-(4-Dimethylaminobenzyl- idene)oxindole	$241$ – $242^e$	$\mathrm{C}_{17}\mathrm{H}_{16}\mathrm{N}_{2}\mathrm{O}$				
4	1-(4-Dimethylaminocinnam- ylidene)indene	205-208/	$\mathrm{C}_{20}\mathrm{H}_{19}\mathrm{N}$				
5	5-(4-Dimethylaminobenzyl- idene)hydantoin	$286-288^{g}$	$C_{12}H_{13}N_3O_2$				
6	2'-Chloro-4-methylamino- stilbene <sup>h</sup>	$40 - 41^{i}$	$\mathrm{C}_{15}\mathrm{H}_{14}\mathrm{N}\mathrm{Cl}^{j}$				
7	2,5-Dimethoxystilbene <sup>h</sup>	$51^{i}$	$\mathrm{C_{16}H_{16}O_2}{}^{j}$				

<sup>a</sup> Determined with Mel-Temp apparatus. Recrystallization solvents are given as footnotes for each compound. <sup>b</sup> All compounds were analyzed for C and H by Galbraith Laboratories except where indicated otherwise. Analytical results obtained were within  $\pm 0.3\%$  of the theoretical values. <sup>c</sup> Pentane and absolute EtOH. <sup>d</sup> i-PrOH. <sup>e</sup> 95% EtOH and C<sub>6</sub>H<sub>6</sub>. <sup>f</sup> Absolute ethanol. Chromatographed on Florisil with C<sub>6</sub>H<sub>6</sub>, then recrystallized. <sup>a</sup> 95% EtOH. <sup>b</sup> Test results not available for these compounds in the Walker system. <sup>i</sup> Purified by chromatographing on Florisil with C<sub>6</sub>H<sub>6</sub>. <sup>j</sup> Analysis by Weiler and Strauss.

testing against the Walker 256 tumor. It was effective at dose levels of 240-1500 mg/kg without killing any of the animals, whereas the  $\rm NH_2$  compound was more toxic, killing two of the test animals at 625 mg/kg, but was more effective than the  $\rm N(CH_3)_2$  compounds at lower dose levels.

2-(4-Aminophenyl)indole, prepared by catalytic reduction of the 4-nitro compound<sup>3</sup> with Pd catalyst in EtOAc, can be considered as a *trans*-4-aminostilbene, but was inactive against the Walker tumor (Table II).

3-(4-Dimethylaminobenzylidene)oxindole, an analog of 1-(4-dimethylaminobenzylidene)-2-indanone, was prepared by the usual KOH-catalyzed condensation method. It was inactive against the Walker tumor.

TABLE II

	KB cell test, <sup>6</sup>	Tumor wt		Lethality	
	$\mathrm{ED}_{M}$ ,				
No.	$\mu g/ml$	T/C	mg/kg	killed	mg/kg
1		0.5	240	0/3	1500
		0.2	600		
$\overline{2}$		1.0	$400^{J}$	0/6	$400^{d}$
3	100	0.8	1280	0/3	1280
4	100	1.0	1500	0/3	1500
$\bar{\mathbf{o}}$		0.9	1600	0/3	1600
6	6				

"See Table I for names of compounds, "Results of the standard in vitro KB tumor cell inhibition tests carried out under sponsorship of the Cancer Chemotherapy National Service Center at Southern Research Institute and University of Miami Cell Culture Laboratory. We are grateful to Professor Sir Alexander Haddow, Mr. J. E. Everett, and Mr. C. V. Mitchley of the Chester Beatty Research Institute for data on toxicity and activity against the Walker 256 tumor in rats weighing 200-250 g. Each compound was admintered as a single intraperitoneal injection in arachis oil on the day following tumor implantation or on the first day of the toxicity observation. Tumor-bearing animals were sacrificed approximately 8 days later. d We are grateful to CCNSC for screening tests against Walker 256 in random-bred albino rats, using four daily intraperitoneal injections in CMC or peannt oil administered 3 days after inplantation and sacrificed 7 days after implantation.

The importance of space relations in determining the activity of 1-(4-dimethylaminobenzylidene)indene is demonstrated by the inactivity of 1-(4-dimethylaminocinnamylidene)indene in which the conjugated series of double bonds has been lengthened to the extent of one more ethylene group. 5-(4-Dimethylaminobenzylidene)hydantoin was inactive and nontoxic.

2'-Chloro-4-methylaminostilbene and 2,5-dimethoxystilbene were prepared by treating the appropriate aldehyde with Grignard reagent prepared from benzyl chloride or 2-chlorobenzyl chloride. The 2'-chloro compound was more toxic in KB cell culture than the methoxy compound.

## 9-(4-Aminobenzylidene)fluorenes1

CARL TABB BAHNER AND DAVID BROTHERTON

Department of Chemistry, Carson-Newman College, Jefferson City, Tennessee 37760

Received March 6, 1969

Haddow, et al., found that 9-(4-dimethylaminobenzylidene)fluorene (I) had some antitumor effect. We have synthesized I and three of its analogs shown in Table I. The Walker 256 tumor inhibition test as now carried out is apparently less sensitive than the test originally used, since the only carcinostatic result obtained was a 38% reduction in the size of tumors treated with 9-(4-methylaminobenzylidene)fluorene. The ED<sub>50</sub> values in the standard KB tissue culture tests were of the same order of magnitude as for the 1-(4-methylaminobenzylidene)indene.

<sup>(1)</sup> This investigation was supported by Public Health Service Research Grants CA-03717-05-11 from the National Cancer Institute.

<sup>(2)</sup> J. Gelzer and P. Loustalot, European J. Cancer, 3, 79 (1967).

<sup>(3)</sup> C. E. Blades and A. L. Wilds, J. Org. Chem., 21, 1013 (1956).

<sup>(1)</sup> This investigation was supported by Public Health Service Research Grants CA-03717-07 and -08 from the National Cancer Institute.

<sup>(2)</sup> A Haddow, R. J. C. Harris, G. A. R. Kon, and E. M. F. Roe, Phil. Trans. Roy. Soc. Lon., 241, 149 (1948).

<sup>(3)</sup> C. T. Bahner, H. Kinder, D. Brotherton, J. Spiggle, and L. Gutman, J. Med. Chem., 3, 390 (1965).